Oncolytic Virus Therapy Market to Witness 20.3% CAGR Boom Through 2022-27 – Latest MarkNtel Advisors Report

0
19
Oncolytic Virus Therapy Market Share, Oncolytic Virus Therapy Market Size, Oncolytic Virus Therapy Market Trends

Market Overview: Global Oncolytic Virus Therapy Market

MarkNtel Advisors, a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. Recently published a report on the Global Oncolytic Virus Therapy Market and provide your business with the latest market trends and analysis from our reports to make informed decisions and stay ahead of the competition.

Oncolytic Virus Therapy Market Insights 2022-27

The Global Oncolytic Virus Therapy Market is projected to grow at a CAGR of around 20.3% during the forecast period i.e. 2022-27.

In case you missed it, we are currently revising our reports. Click on the “request sample report” button to get the latest research data with forecast for the years 2024 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.

Top Players in the Oncolytic Virus Therapy Market:

  • Amgen Inc.
  • Daiichi Sankyo Company Limited
  • DNAtrix
  • Genelux Corporation
  • Oncolytics Biotech Inc.
  • PsiOxus Therapeutics
  • RIGVIR Ltd.
  • Shanghai Sunway Biotech Co. Ltd.
  • SillaJen Inc.
  • Sorrento Therapeutics Inc.
  • Takara Bio Inc.
  • Lokon Pharma AB
  • VCN Biosciences
  • ViroCure Inc.
  • Viralytics Ltd. (Merck & Co. Inc.)

Segmentation Analysis of Oncolytic Virus Therapy Market

Oncolytic Virus Therapy Market exactly assesses and highlights significant trends and influencing factors within each segment. The comprehensive analysis extends its predictions for the period spanning 2022-27, focusing on the national landscape. The market is exactly categorized based on this analysis, providing valuable insights into its various facets.

-By Application

  • Solid Tumor
  • Melanoma
  • Hematological Malignancies

Melanoma is anticipated to dominate the Global Oncolytic Virus Therapy Market in the coming years. It owes to the increasing cases of this skin cancer among people arising from melanocytes. The early-stage lesions might be curative through complete surgical excision, yet the metastatic melanoma remains therapeutically challenging.

Oncolytic Virus Therapy uses the native or attenuated live viruses to selectively eliminate the melanoma cells & induce systemic tumor-specific immune responses. The treatment for Melanoma has evolved rapidly in recent years and has used intratumoral injections. The first FDA-approved oncolytic virus therapy was in 2015, called Talimogene Laherparepvec (T-VEC). This virus displays improvements in patients with a durable response rate with advanced Melanoma.

Read Full Report -  https://www.marknteladvisors.com/research-library/oncolytic-virus-therapy-market.html

-By Therapy

  • IMLYGIC (Talimogene Laherparepvec)
  • Oncorine
  • RIGVIR Immunotherapy
  • Onyx-15
  • Reolysin

-By Type of Virus

  • Genetically Engineered Oncolytic Virus
  • Oncolytic Wild Type of Viruses

-By End-User

  • Hospitals
  • Clinics
  • Patients
  • Cancer Research Institutes

A Comprehensive Geographical Analysis:

-By Region

  • North America
  • South America
  • Europe
  • The Middle East & Africa
  • Asia-Pacific

North America is projected to attain the largest market share during 2022-27, mainly due to its extensive & superior healthcare infrastructure, coupled with improvised reimbursement policies across various countries. Additionally, the well-established research environment for biotechnologies in the region also significantly contributes to the overall market growth. Besides, the presence of the leading healthcare providers, especially in countries like the US & Canada, coupled with their active participation in the R&D of cancer therapy through massive investments, are other crucial aspects expected to drive the regional market in the coming years.

Recently, Amgen Inc. has received approval from the US Food & Drug Administration (FDA) for a Biologics License Application for IMLYGIC (T-Vec) Therapy. It is principally for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma that is recurrent after the initial surgery.

Request Customization – https://www.marknteladvisors.com/query/request-customization/oncolytic-virus-therapy-market.html

Why Choose Us?

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.

Being one of the most efficient market research companies in India, our specialized team of experienced & efficient market research professionals is capable of grasping every minute and valuable information & data of the market to offer our clients with satisfactory details. Our company has served the biggest market research firms in India at leading positions and is proficient in managing all types of market research projects.

More Reports:

https://plaza.rakuten.co.jp/insightpulse/diary/202402120000/

https://plaza.rakuten.co.jp/insightpulse/diary/202402120001/

https://plaza.rakuten.co.jp/insightpulse/diary/202402090000/

https://plaza.rakuten.co.jp/insightpulse/diary/202402090001/

About Us

MarkNtel Advisors is a leading market research company, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.

Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 120.3 diverse industrial verticals.

Media Representative 

Company Name: MarkNtel Advisors

Email:sales@marknteladvisors.com

Phone: +1 628 895 8081, +91 120 4278433